HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases

Journal of Proteomics

Volumn 133, Issue , 2016, Pages 125-133

  Lillico, Ryan ^a   Sobral, Marina Gomez ^a   Stesco, Nicholas ^a   Lakowski, Ted M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Epigenetics; HDAC inhibitor; Histone acetylation; Histone methylation; LC MS MS; Lysine demethylase

Indexed keywords

ARGININE; ENTINOSTAT; HISTONE DEMETHYLASE; HISTONE H3; LYSINE; LYSINE DEMETHYLASE; MOCETINOSTAT; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG; VORINOSTAT; HISTONE; HISTONE DEACETYLASE INHIBITOR;

ARTICLE; CELL CULTURE; COLORIMETRY; CONTROLLED STUDY; ENZYME INHIBITION; HEK293 CELL LINE; HISTONE ACETYLATION; HISTONE METHYLATION; HYDROLYSIS; K562 CELL LINE; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; K-562 CELL LINE; METABOLISM; METHYLATION;

ARGININE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEMETHYLASES; HISTONES; HUMANS; K562 CELLS; LYSINE; METHYLATION; TANDEM MASS SPECTROMETRY;

EID: 84954117503     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.12.018     Document Type: Article

References (40)

1. Rothbart S.B., Strahl B.D. Interpreting the language of histone and DNA modifications. Biochim. Biophys. Acta 1839, 2014:627-643.
2. Rosenfeld M.G., Lunyak V.V., Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006, 20:1405-1428.
3. Gorisch S.M., Wachsmuth M., Toth K.F., Lichter P., Rippe K. Histone acetylation increases chromatin accessibility. J. Cell Sci. 2005, 118:5825-5834.
4. Ramos Y.F., Hestand M.S., Verlaan M., Krabbendam E., Ariyurek Y., van Galen M., et al. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res. 2010, 38:5396-5408.
5. Marquard L., Gjerdrum L.M., Christensen I.J., Jensen P.B., Sehested M., Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008, 53:267-277.
6. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
7. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
8. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., et al. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
9. Kirmizis A., Santos-Rosa H., Penkett C.J., Singer M.A., Vermeulen M., Mann M., et al. Arginine methylation at histone H3R2 controls deposition of H3K4 trimethylation. Nature 2007, 449:928-932.
10. Hyllus D., Stein C., Schnabel K., Schiltz E., Imhof A., Dou Y., et al. PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev. 2007, 21:3369-3380.
11. Iberg A.N., Espejo A., Cheng D., Kim D., Michaud-Levesque J., Richard S., et al. Arginine methylation of the histone H3 tail impedes effector binding. J. Biol. Chem. 2008, 283:3006-3010.
12. + T cells. J. Immunol. 2014, 193:412-421.
13. Feng Y., Wang J., Asher S., Hoang L., Guardiani C., Ivanov I., et al. Histone H4 acetylation differentially modulates arginine methylation by an in Cis mechanism. J. Biol. Chem. 2011, 286:20323-20334.
14. Jiang Y.H., Bressler J., Beaudet A.L. Epigenetics and human disease. Annu. Rev. Genomics Hum. Genet. 2004, 5:479-510.
15. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
16. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
17. Hymes K.B. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. Clin. Lymphoma Myeloma Leuk. 2010, 10:98-109.
18. Halsall J., Gupta V., O'Neill L.P., Turner B.M., Nightingale K.P. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors. PLoS One 2012, 7.
19. Emanuele S., Lauricella M., Carlisi D., Vassallo B., D'Anneo A., Di Fazio P., et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor bortezomib. Apoptosis 2007, 12:1327-1338.
20. Kennedy P.J., Feng J., Robison A.J., Maze I., Badimon A., Mouzon E., et al. Class I HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation. Nat. Neurosci. 2013, 16:434-440.
21. Nightingale K.P., Gendreizig S., White D.A., Bradbury C., Hollfelder F., Turner B.M. Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J. Biol. Chem. 2007, 282:4408-4416.
22. Huang P.H., Chen C.H., Chou C.C., Sargeant A.M., Kulp S.K., Teng C.M., et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol. Pharmacol. 2011, 79:197-206.
23. Daigle S.R., Olhava E.J., Therkelsen C.A., Majer C.R., Sneeringer C.J., Song J., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
24. Lakowski T.M., Szeitz A., Pak M.L., Thomas D., Vhuiyan M.I., Kotthaus J., et al. MS(3) fragmentation patterns of monomethylarginine species and the quantification of all methylarginine species in yeast using MRM(3). J. Proteome 2013, 80:43-54.
25. Lakowski T.M., Frankel A. Kinetic analysis of human protein arginine N-methyltransferase 2: formation of monomethyl- and asymmetric dimethyl-arginine residues on histone H4. Biochem. J. 2009, 421:253-261.
26. 'tHart P., Thomas D., van Ommeren R., Lakowski T.M., Frankel A., Martin N.I. Analogues of the HIV-Tat peptide containing Nη-modified arginines as potent inhibitors of protein arginine N-methyltransferases. Med. Chem. Commun. 2012, 3:1235.
27. Lakowski T.M., Frankel A. A kinetic study of human protein arginine N-methyltransferase 6 reveals a distributive mechanism. J. Biol. Chem. 2008, 283:10015-10025.
28. Lakowski T.M., Zurita-Lopez C., Clarke S.G., Frankel A. Approaches to measuring the activities of protein arginine N-methyltransferases. Anal. Biochem. 2010, 397:1-11.
29. + leukemia cells in vitro and in vivo. Clin. Cancer Res. 2013, 19:404-414.
30. Huang Y., Chen J., Lu C., Han J., Wang G., Song C., et al. HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation. Cell Death Dis. 2014, 5.
31. Edrissi B., Taghizadeh K., Dedon P.C. Quantitative analysis of histone modifications: formaldehyde is a source of pathological n(6)-formyllysine that is refractory to histone deacetylases. PLoS Genet. 2013, 9.
32. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 2009, 107:600-608.
33. Pai C.-C., Deegan R.S., Subramanian L., Gal C., Sarkar S., Blaikley E.J., et al. A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice. Nat. Commun. 2014, 5.
34. Schwartz S., Meshorer E., Ast G. Chromatin organization marks exon-intron structure. Nat. Struct. Mol. Biol. 2009, 16:990-995.
35. Portela A., Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28:1057-1068.
36. Marinova Z., Leng Y., Leeds P., Chuang D.M. Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology 2011, 60:1109-1115.
37. Duque-Afonso J., Yalcin A., Berg T., Abdelkarim M., Heidenreich O., Lubbert M. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene 2011, 30:3062-3072.
38. Göttlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20:6969-6978.
39. Ganai S.A., Malli Kalladi S., Mahadevan V. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells. J. Biomol. Struct. Dyn. 2014, 1-13.
40. Wang Z., Patel D.J. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases. Q. Rev. Biophys. 2013, 46:349-373.